Results 81 to 90 of about 8,720 (195)

Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects) [PDF]

, 2008
BackgroundCilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD). At the time of approval, the United States Food and
Brass, Eric P., Hiatt, William R., Money, Samuel R.   +2 more
core   +1 more source

Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity

, 2022
Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a key role in cholesterol homeostasis. Cilostazol exerts favorable cellular and metabolic effects; however, the effect of cilostazol on the expression of PCSK9 has not been previously reported ...
Po-Wei Chen, Chao, Ting-Hsing, Chang, Hsien-Yuan, Shih-Ya Tseng, Chen, Po-Wei, Hsien-Yuan Chang, Tseng, Shih-Ya, Lee, Cheng-Han, Cheng-Han Lee, Ting-Hsing Chao   +9 more
core   +1 more source

Cilostazol Combats Lipopolysaccharide-Induced Hippocampal Injury in Rats: Role of AKT/GSK3β/CREB Curbing Neuroinflammation

Advances in Pharmacological and Pharmaceutical Sciences
Neuroinflammation is important in the pathophysiology of several degenerative brain disorders. This study looked at the potential neuroprotective benefits of cilostazol, a phosphodiesterase inhibitor, against LPS-induced hippocampus damage in rodents and
Doaa Abou El-ezz, Waleed Aldahmash, Tuba Esatbeyoglu, Sherif M. Afifi, Marawan Abd Elbaset   +4 more
doaj   +1 more source

Sustained Effectiveness of Cilostazol After Endovascular Treatment of Femoropopliteal Lesions: Midterm Follow-up From the Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) Study

, 2018
Purpose: To investigate the midterm safety and effectiveness of cilostazol treatment in claudicant patients undergoing endovascular therapy. Methods: The Sufficient Treatment of Peripheral Intervention by Cilostazol (STOP-IC) study ( ClinicalTrials.gov ...
Kenji Suzuki, Toshimitsu Hamasaki, Osamu Iida, Yoshimitsu Soga, Daizo Kawasaki, Naoto Inoue, Kan Zen, Kazushi Urasawa, Kenji Aodo, Ryuya Edahiro, Yoshiaki Yokoi   +10 more
core   +1 more source

The drug risks of cilostazol: A pharmacovigilance study of FDA Adverse Event Reporting System database.

PLoS ONE
ObjectiveCilostazol is indicated for alleviating intermittent claudication (IC) in stable-phase peripheral arterial disease (PAD) patients. Conducting data mining on adverse events (AEs) of cilostazol in the U.S.
Lufeng Peng, Xueli Li, Junhai Li, Shibin Liu, Gang Liang   +4 more
doaj   +1 more source

Cilostazol: an antiplatelet agent for the neurointerventionist?

Journal of NeuroInterventional Surgery, 2014
Antiplatelet agents are essential for the successful management of patients undergoing a variety of neurointerventional procedures. The most commonly used anti-platelet agents are aspirin, clopidogrel and prasugrel. However, there exist an alternative class of anti-platelet agent that may prove useful for neurointerventionists.
Bhogal, P., Brouwer, P.A., Makalanda, H.L.D.   +2 more
openaire   +3 more sources

Curcumin increases vasodilatory effect of cilostazol in diabetic rat aorta

, 2012
128-132Increased generation of oxidants and (or) reduced endogenous antioxidant defense mechanisms are associated with the etiology of diabetic vascular complications.
Okudan, N, Şimşek, L, Gökbel, H, Nurullahoğlu-Atalık, K E, Belviranlı, M   +4 more
core   +1 more source

β-aminopropionitrile-induced thoracic aortopathy is refractory to cilostazol and sildenafil in mice.

PLoS ONE
Thoracic aortopathies are life-threatening diseases including aneurysm, dissection, and rupture. Cilostazol, a phosphodiesterase (PDE) 3 inhibitor, and sildenafil, a PDE5 inhibitor, have been used clinically for peripheral arterial disease and erectile ...
Samuel C Tyagi, Sohei Ito, Jacob C Hubbuch, Michael K Franklin, Deborah A Howatt, Hong S Lu, Alan Daugherty, Hisashi Sawada   +7 more
doaj   +1 more source

Effects of Isosorbide Mononitrate and/or Cilostazol on Hematological Markers, Platelet Function, and Hemodynamics in Patients With Lacunar Ischaemic Stroke: Safety Data From the Lacunar Intervention-1 (LACI-1) Trial

Frontiers in Neurology, 2019
Background: Cilostazol and isosorbide mononitrate (ISMN) are candidate treatments for cerebral small vessel disease and lacunar ischaemic stroke. As both drugs may influence hemoglobin and platelet count, and hemodynamics, we sought to assess their ...
Jason P. Appleton, Jason P. Appleton, Gordon W. Blair, Gordon W. Blair, Gordon W. Blair, Katie Flaherty, Zhe Kang Law, Zhe Kang Law, Zhe Kang Law, Jane May, Lisa J. Woodhouse, Fergus Doubal, Fergus Doubal, Fergus Doubal, Nikola Sprigg, Nikola Sprigg, Philip M. Bath, Philip M. Bath, Joanna M. Wardlaw, Joanna M. Wardlaw, Joanna M. Wardlaw   +20 more
doaj   +1 more source

Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique

BMC Neurology, 2017
Background In order to evaluate the impact of cilostazol on endothelial function, we compared the changes of flow-mediated dilation (FMD) between aspirin and cilostazol groups in patients with acute cerebral ischemia.
Seong-Joon Lee, Jin Soo Lee, Mun Hee Choi, Sung Eun Lee, Dong Hoon Shin, Ji Man Hong   +5 more
doaj   +1 more source